Aligos Therapeutics Inc. (ALGS) stock has reached a new 52-week high, touching $44.5 as the company rides a wave of positive momentum. According to InvestingPro data, the stock has delivered impressive returns of nearly 330% over the past six months, though technical indicators suggest the stock may be overbought. This significant price level marks a notable milestone for the biopharmaceutical company, reflecting a substantial increase of 144.62% in its stock value over the past year. While investors have shown increased confidence in Aligos Therapeutics, InvestingPro analysis indicates the company is rapidly burning through cash and currently trades above its Fair Value. The company maintains a healthy balance sheet with more cash than debt, though analysts don't expect profitability this year. The 52-week high serves as a testament to the company's recent market performance, despite these fundamental challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.